Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Overview

About this study

The purpose of this study is to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary effectiveness of JANX007 administered as a single agent in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Male subjects ≥18 years of age at the time of signing informed consent

- Histologically or cytologically confirmed adenocarcinoma of the prostate

- Subjects with mCRPC who progressed after at least one novel anti-androgen therapy and
at least one taxane containing regimen. Subjects who have actively refused a taxane
containing regimen or are medically unsuitable to receive taxane are eligible

- PSMA expressing tumor

- Adequate organ function

Exclusion Criteria:

- Prior solid organ transplant

- Prior treatment with PSMA-targeted CAR-T cell therapy

- Clinically significant cardiovascular disease

- Active clinically significant infection (bacterial, viral, fungal, mycobacteria or
other)

- Any medical condition or clinical laboratory abnormality likely to interfere with
assessment of safety or efficacy of study treatment

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 10/24/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Winston Tan, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Lance Pagliaro, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Parminder Singh, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available